SEC Comment Letter 0000000000-23-014200 to FSD Pharma Inc. (QNTM) (CIK 0001771885) (QNTM)
FSD Pharma Inc. (QNTM) (CIK 0001771885)
Date: Dec. 29, 2023 · CIK: 0001771885 · Accession: 0000000000-23-014200
AI Filing Summary & Sentiment
File numbers found in text: 333-276264
Letter
United States securities and exchange commission logo December 29, 2023 Zeeshan Saeed Chief Executive Officer FSD Pharma Inc. 199 Bay Street, Suite 4000 Toronto, Ontario M5L 1A9, Canada Re:FSD Pharma Inc. Registration Statement on Form F-3 Filed December 26, 2023 File No. 333-276264 Dear Zeeshan Saeed: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel Nauth, Esq.
Show Raw Text
United States securities and exchange commission logo
December 29, 2023
Zeeshan Saeed
Chief Executive Officer
FSD Pharma Inc.
199 Bay Street, Suite 4000
Toronto, Ontario M5L 1A9, Canada
Re:FSD Pharma Inc.
Registration Statement on Form F-3
Filed December 26, 2023
File No. 333-276264
Dear Zeeshan Saeed:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel Nauth, Esq.